CA
EFTRW

Cetera Advisors’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Cetera Advisors’s Portfolio EFTRW Stock Details EFTRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$16K – 1531
2021
Q3 		$16K Buy
+10,000
New +$12.1K ﹤0.01% 1398

Other funds holding EFTRW

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
ICMH
Integrity Capital Management (HK) Central, Hong Kong $64K AUM
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Cetera Advisors's EFTRW Position: Q4 2021 in Review

Cetera Advisors sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q4 2021, closing a stake of 10,000 shares — an estimated $16K sold.

Cetera Advisors first reported a position in EFTRW in Q3 2021 and held it in 1 quarter. The position peaked at $16K in Q3 2021. 17 funds tracked by Wall St. Rank hold EFTRW as of Q4 2021.

  • Cetera Advisors reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q4 2021 after selling out during the quarter.
  • Cetera Advisors sold 10,000 eFFECTOR Therapeutics, Inc. Warrant shares in Q4 2021, an estimated $16K.
  • Cetera Advisors first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q3 2021 and held it in 1 quarter.
  • Cetera Advisors's eFFECTOR Therapeutics, Inc. Warrant position peaked at $16K in Q3 2021.
  • 17 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q4 2021.

Based on Cetera Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.